Last reviewed · How we verify
CGB-500 Ointment with 1% tofacitinib
CGB-500 Ointment with 1% tofacitinib is a JAK inhibitor Small molecule drug developed by CAGE Bio Inc.. It is currently in Phase 2 development for Rheumatoid arthritis.
Tofacitinib is a Janus kinase (JAK) inhibitor that suppresses the activity of JAK enzymes, which play a key role in the signaling of cytokines involved in inflammation.
Tofacitinib is a Janus kinase (JAK) inhibitor that suppresses the activity of JAK enzymes, which play a key role in the signaling of cytokines involved in inflammation. Used for Rheumatoid arthritis.
At a glance
| Generic name | CGB-500 Ointment with 1% tofacitinib |
|---|---|
| Sponsor | CAGE Bio Inc. |
| Drug class | JAK inhibitor |
| Target | JAK |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting JAK enzymes, tofacitinib reduces the production of pro-inflammatory cytokines, thereby decreasing inflammation and modulating the immune response. This mechanism of action is thought to contribute to its therapeutic effects in treating various inflammatory conditions.
Approved indications
- Rheumatoid arthritis
Common side effects
- Nausea
- Headache
- Diarrhea
- Fatigue
- Musculoskeletal pain
Key clinical trials
- A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis (PHASE2)
- Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CGB-500 Ointment with 1% tofacitinib CI brief — competitive landscape report
- CGB-500 Ointment with 1% tofacitinib updates RSS · CI watch RSS
- CAGE Bio Inc. portfolio CI
Frequently asked questions about CGB-500 Ointment with 1% tofacitinib
What is CGB-500 Ointment with 1% tofacitinib?
How does CGB-500 Ointment with 1% tofacitinib work?
What is CGB-500 Ointment with 1% tofacitinib used for?
Who makes CGB-500 Ointment with 1% tofacitinib?
What drug class is CGB-500 Ointment with 1% tofacitinib in?
What development phase is CGB-500 Ointment with 1% tofacitinib in?
What are the side effects of CGB-500 Ointment with 1% tofacitinib?
What does CGB-500 Ointment with 1% tofacitinib target?
Related
- Drug class: All JAK inhibitor drugs
- Target: All drugs targeting JAK
- Manufacturer: CAGE Bio Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Compare: CGB-500 Ointment with 1% tofacitinib vs similar drugs
- Pricing: CGB-500 Ointment with 1% tofacitinib cost, discount & access